<DOC>
	<DOCNO>NCT00529802</DOCNO>
	<brief_summary>The purpose study learn PET scan predict degree tumor shrinkage study drug RAD001 subject advanced renal cancer .</brief_summary>
	<brief_title>Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography Predictive Marker Therapy With RAD001 Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Metastatic renal cancer refractory sorafenib sunitinib therapy At least one measurable site disease accord RECIST criterion previously irradiate . 18 year age old Minimum two week since major surgery , completion radiation , completion prior standard systemic anticancer therapy adequately recover acute toxicity prior therapy . World Health Organization ( WHO ) performance status &lt; = 2 Adequate bone marrow function Adequate liver function Adequate creatinine clearance Signed informed consent Prior treatment investigational drug within previous 4 week Chronic treatment systemic steroid another immunosuppressive agent Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases Patients history another primary malignancy â‰¤ 3 year , exception nonmelanoma skin cancer , carcinoma situ uterine cervix Patients severe and/or uncontrolled medical condition condition could affect participation study A known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Patients active , bleed diathesis oral antivitamin K medication Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control enrollment 6 month follow end treatment Patients receive prior treatment mTOR inhibitor . Patients know hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients History noncompliance medical regimen Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>metastatic</keyword>
	<keyword>renal</keyword>
	<keyword>cell</keyword>
	<keyword>carcinoma</keyword>
	<keyword>cancer</keyword>
</DOC>